- Faruqi & Faruqi, LLP is investigating **Jasper Therapeutics (JSPR)** for a federal securities class action lawsuit, with a lead plaintiff deadline of **November 18, 2025**.  **[1788028_9f652e8af46b4954a038f27ba22a5553_1]** 
- The lawsuit alleges that Jasper made false or misleading statements by failing to disclose inadequate controls over third-party manufacturers, which led to confounded clinical trial results and overstated business and financial prospects.  **[1788028_9f652e8af46b4954a038f27ba22a5553_1]** 
- On **July 7, 2025**, Jasper reported issues with a drug product lot that confounded results in the BEACON Study, leading to the halting of the ETESIAN Study and pausing development in asthma and SCID.  **[1788028_9f652e8af46b4954a038f27ba22a5553_2]** 
- Following this announcement, Jasper stated it would implement cost-cutting measures, including a potential restructuring, to extend its cash runway, contradicting prior representations.  **[1788028_9f652e8af46b4954a038f27ba22a5553_2]** 
- Jasper's stock price reacted by falling **$3.73 per share, or 55.1%**, to close at **$3.04 per share** on **July 7, 2025**.  **[1788028_9f652e8af46b4954a038f27ba22a5553_2]**

Jasper Therapeutics Faces Securities Class Action Lawsuit

- Pomerantz LLP has filed a class action lawsuit against **Jasper Therapeutics, Inc. (JSPR)** and certain officers, docketed under 25-cv-08010.  **[1788028_5dfe559d8a964397b3327470b816950d_0]** 
- The class period for the lawsuit is between **November 30, 2023, and July 3, 2025**, and investors have until **November 18, 2025**, to ask the Court to appoint them as Lead Plaintiff.  **[1788028_5dfe559d8a964397b3327470b816950d_0]** 
- The complaint alleges that defendants made materially false and misleading statements regarding the company's business, operations, and compliance policies, specifically concerning the manufacturing of drug products in accordance with cGMP regulations.  **[1788028_5dfe559d8a964397b3327470b816950d_2]** 
- These issues led to a **drug product lot problem** that confounded results in the BEACON Study and ETESIAN Study, resulting in the **halting of the ETESIAN Study**, pausing asthma development, halting SCID development, and implementing **cost-cutting measures**, including a **50% workforce reduction**.  **[1788028_5dfe559d8a964397b3327470b816950d_3]** 
- Following this news on **July 7, 2025**, Jasper's stock price **fell $3.73 per share, or 55.1%**, to close at **$3.04 per share**.  **[1788028_5dfe559d8a964397b3327470b816950d_3]**

Jasper Therapeutics Faces Class Action Lawsuit

- A **class action lawsuit** has been filed against Jasper Therapeutics (JSPR) and certain officers, alleging materially false and misleading statements regarding the company's business, operations, and compliance policies between **November 30, 2023, and July 3, 2025**.  **[1788028_20251013DC96239:0]** **[1788028_20251013DC96239:1]** 
- The lawsuit claims Jasper lacked adequate controls over third-party manufacturers, leading to a **drug product lot issue** that confounded results in the BEACON Study.  **[1788028_20251013DC96239:1]** 
- As a direct consequence of the manufacturing issue, Jasper **halted the ETESIAN Study** in asthma, **paused development in SCID**, and announced **cost-cutting measures** including a potential restructuring.  **[1788028_20251013DC96239:1]** 
- Following the announcement of the drug lot issue on **July 7, 2025**, Jasper's stock price **fell $3.73 per share, or 55.1%, to $3.04 per share**.  **[1788028_20251013DC96239:1]** 
- On **July 9, 2025**, the company announced a **corporate reorganization**, including a **50% workforce reduction** and the departure of its Chief Medical Officer, to focus resources on briquilimab in chronic urticaria.  **[1788028_20251013DC96239:2]**

Jasper Therapeutics Faces Class Action Lawsuit Over Alleged Misleading Statements and Manufacturing Issues

- Pomerantz LLP has filed a class action lawsuit against **Jasper Therapeutics, Inc.** and certain officers, alleging violations of federal securities laws during the **Class Period of November 30, 2023, to July 3, 2025**.  **[1788028_20251008DC93554:0]** 
- The lawsuit claims Jasper made false and misleading statements, particularly regarding a lack of controls to ensure third-party manufacturers complied with cGMP regulations, which led to confounded results in clinical trials.  **[1788028_20251008DC93554:1]** 
- On **July 7, 2025**, Jasper reported a drug product lot issue in its BEACON Study, which also affected the ETESIAN Study, leading to the halting of development in asthma and SCID, and a subsequent **55.1% drop in stock price**.  **[1788028_20251008DC93554:1]** 
- Following these issues, Jasper announced a corporate reorganization on **July 9, 2025**, including a **50% workforce reduction** and the departure of the Chief Medical Officer, to focus resources on briquilimab in chronic urticaria.  **[1788028_20251008DC93554:1]** **[1788028_20251008DC93554:2]**

Pomerantz LLP Files Class Action Lawsuit Against Jasper Therapeutics

- Faruqi & Faruqi, LLP is investigating **Jasper Therapeutics** (NASDAQ: JSPR) for potential federal securities law violations, with a **November 18, 2025 deadline** for investors to seek the role of lead plaintiff in a federal securities class action.  **[1788028_7d62def0d88e4b70a12e2522d4e3c374_1]** 
- The complaint alleges that Jasper lacked necessary controls for third-party manufacturers, which increased the risk of confounded clinical trial results for products like briquilimab and led to overstated business and financial prospects.  **[1788028_7d62def0d88e4b70a12e2522d4e3c374_1]** 
- On **July 7, 2025**, Jasper reported issues with a drug product lot in the BEACON Study, leading to the halting of development in asthma and SCID, and plans for cost-cutting measures.  **[1788028_7d62def0d88e4b70a12e2522d4e3c374_2]** 
- Following this news, Jasper's stock price fell **$3.73 per share**, or **55.1%**, to close at **$3.04 per share** on **July 7, 2025**.  **[1788028_7d62def0d88e4b70a12e2522d4e3c374_2]**

Jasper Therapeutics Faces Securities Class Action Investigation

- Faruqi & Faruqi, LLP is investigating **Jasper Therapeutics, Inc. (JSPR)** for potential federal securities law violations, with a **November 18, 2025, deadline** for investors to seek the role of lead plaintiff.  **[1788028_b777f364f72c4b2bbb17b093f7db805f_1]** 
- The investigation concerns investors who purchased or acquired securities in Jasper between **November 30, 2023, and July 3, 2025**.  **[1788028_b777f364f72c4b2bbb17b093f7db805f_0]** 
- Allegations include Jasper lacking controls for third-party manufacturers, leading to confounded study results for products like briquilimab, and overstating the company's business and financial prospects.  **[1788028_b777f364f72c4b2bbb17b093f7db805f_1]** 
- On **July 7, 2025**, Jasper reported an issue with a drug product lot affecting the BEACON and ETESIAN studies, resulting in the halting of the ETESIAN study, pausing asthma development, halting SCID development, and plans for cost-cutting measures.  **[1788028_b777f364f72c4b2bbb17b093f7db805f_2]** 
- Following this announcement, Jasper's stock price **fell $3.73 per share, or 55.1%**, to close at **$3.04 per share** on **July 7, 2025**.  **[1788028_b777f364f72c4b2bbb17b093f7db805f_2]**

Faruqi & Faruqi Investigates Jasper Therapeutics for Securities Law Violations

- Faruqi & Faruqi, LLP is investigating **Jasper Therapeutics (NASDAQ: JSPR)** for alleged federal securities law violations, with a deadline for investors to seek lead plaintiff status by **November 18, 2025**.  **[1788028_20251003NY88537:0]** 
- The complaint alleges the company made false or misleading statements regarding its manufacturing controls, which led to issues with a drug product lot used in the BEACON and ETESIAN studies.  **[1788028_20251003NY88537:0]** 
- As a result, Jasper halted the ETESIAN study, paused development in asthma, halted development in SCID, and announced cost-cutting measures including a potential restructuring.  **[1788028_20251003NY88537:0]** 
- Following these disclosures on July 7, 2025, Jasper's stock price **fell $3.73 per share, or 55.1%**, to close at **$3.04 per share**.  **[1788028_20251003NY88537:0]**

- Pomerantz LLP has filed a class action lawsuit against **Jasper Therapeutics, Inc. (JSPR)** and certain officers, on behalf of investors who purchased securities between **November 30, 2023, and July 3, 2025**.  **[1788028_20251003DC87782:0]** 
- The lawsuit alleges that Jasper made materially false and misleading statements, specifically regarding its lack of controls over third-party manufacturers' compliance with cGMP regulations, which increased the risk of confounded study results and overstated the company's business and financial prospects.  **[1788028_20251003DC87782:1]** 
- On **July 7, 2025**, Jasper announced issues with a drug product lot in its BEACON Study, leading to the halting of the ETESIAN Study and SCID development, and a subsequent **55.1% drop in stock price** to **$3.04 per share**.  **[1788028_20251003DC87782:1]** 
- Following this news, Jasper announced a corporate reorganization, including a **50% workforce reduction**, halting other clinical and preclinical programs to focus on chronic urticaria, and the departure of its Chief Medical Officer effective August 1, 2025.  **[1788028_20251003DC87782:2]**

- Faruqi & Faruqi, LLP is investigating potential claims against **Jasper Therapeutics (JSPR)**, and a federal securities class action has been filed with a lead plaintiff deadline of **November 18, 2025**.  **[1788028_9eec50e97f7044de83f651894d63493a_1]** 
- The complaint alleges that Jasper made false and/or misleading statements and failed to disclose issues with third-party manufacturers, which led to confounded results in clinical trials for products such as briquilimab.  **[1788028_9eec50e97f7044de83f651894d63493a_1]** 
- This issue, involving a problematic drug product lot in the BEACON Study, resulted in the halting of the ETESIAN Study and pausing development in asthma and SCID.  **[1788028_9eec50e97f7044de83f651894d63493a_2]** 
- Following this disclosure on **July 7, 2025**, Jasper's stock price fell **$3.73 per share, or 55.1%**, to close at **$3.04 per share**.  **[1788028_9eec50e97f7044de83f651894d63493a_2]** 
- Investors who incurred losses between **November 30, 2023, and July 3, 2025**, are encouraged to contact the firm.  **[1788028_9eec50e97f7044de83f651894d63493a_0]**

- A class action lawsuit has been filed by Pomerantz LLP against **Jasper Therapeutics (JSPR)** and certain officers, covering the period from **November 30, 2023, to July 3, 2025**.  **[1788028_20250928DC83431:0]** 
- The lawsuit alleges that Jasper made materially false and misleading statements regarding its manufacturing controls and compliance with cGMP regulations, which led to issues with drug product lots used in clinical trials.  **[1788028_20250928DC83431:1]** 
- On **July 7, 2025**, Jasper announced a drug product lot issue that confounded results in its BEACON Study and led to the halting of the ETESIAN Study and SCID development, causing its stock price to **fall $3.73 per share, or 55.1%**, to close at **$3.04 per share**.  **[1788028_20250928DC83431:1]** 
- Following these revelations, on **July 9, 2025**, Jasper announced a corporate reorganization, including a **50% workforce reduction** and the departure of its Chief Medical Officer, to extend its cash runway.  **[1788028_20250928DC83431:2]**